Eric Donnenfeld, MD, sat down to discuss presentations on the novel new artificial tear, Blink Triple Care, about its efficacy in a non-controlled trial as well as comparison to the Classic Blink at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
At this year's ARVO meeting, Neda Gioia, OD, discussed the increasing patient burden of dry eye disease
Eric Donnenfeld, MD, discusses the clinical evaluation of Blink Triple Care artificial tears ahead of the 2024 ARVO meeting
John Sheppard, MD, MSc, FACs, discusses the unique biochemical traits of perfluorohexyloctane for eye dry disease and meibomian gland dysfunction
Paul Kayne, PhD gave an onsite overview of his poster at the 2024 ARVO meeting
News
In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.
Osamah Saeedi, MD, MS, discusses his poster presentation from the ARVO Imaging in the Eye conference
At the ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Giulia Corradetti, MD about AMD.
Investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years. The children with CVI underwent a complete pediatric neuro-ophthalmologic examination.
Investigators say children with cortical/cerebral visual impairment experience markedly lower vision-specific quality of life
Barry Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California Irvine, speaks about his ARVO poster presentation
Investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years. The children with CVI underwent a complete pediatric neuro-ophthalmologic examination.
Paolo Silva, MD, speaks on the effect of diabetic retinopathy lesion location and long-term risk of progression
Cynthia Roberts, PhD, sat down to discuss a 5-year prospective study to compare ocular stiffness parameters in, diabetes with retinopathy, diabetes without retinopathy, and normal subjects at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
Qinqin Zhang, PhD, presented on a deep learning model for GA segmentation at this year's ARVO meeting
Researchers conducted a retrospective chart review to identify the clinical characteristics of the injured eyes that may be associated with visual recovery in this patient population.
At this year's ARVO meeting, Ash Abbey, MD, presented 36-month data from the GALE study of pegcetacoplan
Priorities can ensure optimal outcomes for patients diagnosed with diseases.
News
A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed diverse retina-related challenges and unveiled findings with the potential to revolutionize vision science.
Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.
Amitha Domalpally, MD, PhD, discusses how disorganization of retinal inner layers affects OCT outcomes in cases of uveitic macular edema.
In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.
The investigators conducted a retrospective chart review of patients’ demographic and clinical data from 2005 to 2020.
Study results indicate that maintaining control of blood pressure and hemoglobin A1c are key to preventing the onset of diabetic retinopathy
At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.
In this investigation, the second stage of the CHAMP phase 3 trial assessed the impact of prolonging drug administration for an extra 12 months on myopia control and the occurrence of myopia rebound upon cessation of dosing.
This study also investigated the development of myopia rebound when dosing was discontinued
Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration
